Erenumab
- Generic Name
- Erenumab
- Brand Names
- Aimovig
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1582205-90-0
- Unique Ingredient Identifier
- I5I8VB78VT
- Background
Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specificall...
- Indication
Erenumab is indicated for the preventative treatment of migraine in adults .
- Associated Conditions
- Migraine
- Associated Therapies
- -
CGRP Inhibition, Autonomic Function, and Migraine
- Conditions
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 120
- Registration Number
- NCT04628429
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Registry for Migraine - Clinical Core
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04603976
- Locations
- 🇩🇰
Danish Headache Center, Glostrup, Denmark
Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 400
- Registration Number
- NCT04592952
- Locations
- 🇩🇰
Danish Headache Center, Copenhagen, Glostrup, Denmark
The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 72
- Registration Number
- NCT04452929
- Locations
- 🇩🇰
Danish Headache Center, Glostrup, Denmark
Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2021-04-19
- Target Recruit Count
- 40
- Registration Number
- NCT04361721
- Locations
- 🇮🇹
IRCCS Mondino Foundation, Pavia, Italy
Erenumab For Treatment of Hemicrania Continua
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 2
- Registration Number
- NCT04303845
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 65
- Registration Number
- NCT04294147
- Locations
- 🇺🇸
CMR of Greater New Haven, Waterbury, Connecticut, United States
🇺🇸Pharmacology Research Institute, Newport Beach, California, United States
🇺🇸Clinical Research Institute LLC, Los Angeles, California, United States
Biomarker and Genetic Predictors of Erenumab Treatment Response
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1406
- Registration Number
- NCT04265755
- Locations
- 🇩🇰
Glostrup Hospital, Glostrup, Denmark
🇮🇸Thjonustumidstod Rannsoknaverkefna, Reykjavik, Iceland
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 512
- Registration Number
- NCT04252742
- Locations
- 🇺🇸
Chicago Headache Center and Research Institute, Chicago, Illinois, United States
🇺🇸Clinical Research Institute, LLC, Los Angeles, California, United States
🇨🇿Poliklinika Chocen, Neurohk sro, Chocen, Czechia
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 40
- Registration Number
- NCT04179474
- Locations
- 🇺🇸
Spaulding, West Bend, Wisconsin, United States
🇺🇸QPS, Springfield, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.